*Percentages relative to same period last year
PepsiCo
Purchase
Net Income: $1.98B (-2%)
Revenue: $16.9B (+0.5%)
Stock Price, 52-week range: $77.01 – $93.51
2013 Annual Revenue: $66.4B
“Despite operating in what continues to be a challenging and volatile macro environment, we are delivering consistent, strong results. Our results reflect the power of our portfolio of products and brands, and the strength of our geographic footprint. They also reflect the hard work we’ve done to position our business for sustainable success.”
–Indra Nooyi, chairman and CEO
IBM
Armonk
Net Income: $4.1B (+21%)
Revenue: $24.4B (-2%)
Stock Price, 52-week range: $172.19 – $199.21
2013 Annual Revenue: $99.75B
“In the second quarter, we made further progress on our transformation. We performed well in our strategic imperatives around cloud, big data and analytics, security, and mobile. We will continue to extend and leverage our unique strengths to address the emerging trends in enterprise IT and transform our business, positioning ourselves for growth over the long term.”
-Ginni Rometty, IBM chairman, president, and CEO
MasterCard
Purchase
Net Income: $931M (+10%)
Revenue: $2.4B (+13%)
Stock Price, 52-week range: $61.05 – $84.75
2013 Annual Revenue: $7.39B
“We are pleased with another quarter of solid performance, driven by healthy volume and revenue growth. We continue to invest in our strategic initiatives, including acquisitions, while strengthening partnerships with banks, merchants, governments, and mobile operators to grow and improve our business and theirs.”
-Ajay Banga, president and CEO
Regeneron Pharmaceuticals
Tarrytown
Net Income: $92.7M (+6%)
Revenue: $418M (+25%)
Stock Price, 52-week range: $245.99 – $369.31
2013 Annual Revenue: $2.1B
“Regeneron continued to make progress across all aspects of our business, delivering continued growth and another strong quarter. In the last two months alone, we received approval for an additional indication for EYLEA in diabetic macular edema and reported positive clinical results from our late-stage portfolio with alirocumab in hypercholesterolemia, dupilumab in atopic dermatitis, and sarilumab in rheumatoid arthritis.”
-Leonard S. Schleifer, M.D., Ph.D., president and CEO
Acorda Therapeutics
Ardsley
Net Income: $17.7M (+46%)
Revenue: $92.1M (+12%)
Stock Price, 52-week range: $27.51 – $39.95
2013 Annual Revenue: $292M
“AMPYRA sales in the second quarter were strong and we are reiterating our net sales guidance for the year. With six clinical-stage compounds currently in our pipeline, we are creating a diversified portfolio that addresses significant unmet medical needs and drives shareholder value. Our balance sheet puts us in a more competitive position to add new assets to our pipeline, and we are focusing on opportunities that have the potential to be accretive in the near and intermediate term.”
-Ron Cohen, M.D., president and CEO
